Poly(ethylene terephthalate) (PET) is the most common polyester plastic in the packaging industry and a major source of environmental pollution due to its single use. Several enzymes, termed PET hydrolases, have been found to hydrolyze this polymer at different temperatures, with the enzyme from (PETase) having optimal catalytic activity at 30-35 °C. Crystal structures of PETase have revealed that the side chain of a conserved tryptophan residue within an active site loop (W185) shifts between three conformations to enable substrate binding and product release. This is facilitated by two residues unique to PETase, S214 and I218. When these residues are inserted into other PET hydrolases in place of the otherwise strictly conserved histidine and phenylalanine residues found at their respective positions, they enhance activity and decrease . Herein, we combine molecular dynamics and well-tempered metadynamics simulations to investigate dynamic changes of the S214/I218 and H214/F218 variants of PETase, as well as three other mesophilic and thermophilic PET hydrolases, at their respective temperature and pH optima. Our simulations show that the S214/I218 insertion both increases the flexibility of active site loop regions harboring key catalytic residues and the conserved tryptophan and expands the conformational plasticity of this tryptophan side chain, enabling the conformational transitions that allow for substrate binding and product release in PETase. The observed catalytic enhancement caused by this substitution in other PET hydrolases appears to be due to conformational selection, by capturing the conformational ensemble observed in PETase.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080609 | PMC |
http://dx.doi.org/10.1021/acsorginorgau.2c00054 | DOI Listing |
Alzheimers Dement
December 2024
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Gothenburg, Sweden.
Background: Emerging evidence underscores the importance of neuroinflammation in the progression of Alzheimer's disease (AD) pathophysiology. Recent studies indicate the involvement of the inflammatory mechanisms both in amyloid- β (Aβ) and tau deposition in the brain. Nevertheless, due to the complexity of the immune responses and the intricate interplay between the peripheral and the central nervous systems, identifying biomarkers that reflect the brain´s inflammatory state in AD has been a challenge.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Background: A rare reelin gene variant (RELN-COLBOS mutation) delayed dementia onset in almost 30 years in an autosomal dominant Alzheimer's disease (ADAD) carrier. This patient presented with high amyloid-β (Aβ) plaque load, but low tau accumulation, suggesting that this single-nucleotide polymorphism (SNP) in RELN conferred a resilience not only to cognitive decline but also to tauopathy in ADAD. However, whether RELN SNPs are also protective in sporadic Alzheimer's disease (AD) is yet to be determined.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Science and Technology of China, Hefei, Anhui, China.
Background: The exact impacts of β-site APP cleaving enzyme (BACE1) on brain atrophy and cognitive decline in the Alzheimer's disease (AD) remain not fully understood. This study aimed to investigate the relationship between BACE1 in cerebrospinal fluid (CSF) and amyloid-β (Aβ) pathology, neurodegeneration and cognitive function.
Method: This study involved 359 participants from original individuals of the China Aging and Neurodegenerative Disorder Initiative (CANDI) cohort, who underwent measurements of AD biomarkers.
Alzheimers Dement
December 2024
Thai Red Cross Emerging Infectious Diseases Health Science Centre, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Alzheimer's disease (AD) is referred as one of the most common causes of dementia and frailty. To address this impending public health crisis, there is a critical need to identify simple and reliable biomarkers for early AD diagnosis. Recent research has highlighted the potential utility of salivary lactoferrin (Lf) as a promising biomarker for AD diagnosis.
View Article and Find Full Text PDFBackground: We evaluated whether baseline differences existed in various plasma Alzheimer's disease (AD) biomarkers in cognitively normal participants racialized as Black or White.
Method: This cross-sectional study included 203 (n=83 non-Hispanic Black [NHB] and n=120 non-Hispanic White [NHW]) cognitively unimpaired older adults from the NYU Alzheimer's Disease Research Center. Of the 203, 115 (39NHB, 76 NHW) had tau-PET (PI-2620/MK-6240) data; 195 (85 NHB, 110 NHW) had amyloid-PET (florbetaben); 98 (39 NHB, 59 NHW) had plasma Aβ40 and Ab42 data, 93 (37 NHB, 56 NHW) had data for total tau, 135 (55 NHB, 80 NHW) had neurofilament light (NfL) and glial fibrillary protein (GFAP) data and 139 (57 NHB, 82 NHW) had pTau181 data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!